Logo image
Current challenges in the development of new treatments for lupus
Journal article   Peer reviewed

Current challenges in the development of new treatments for lupus

Maria Dall'Era, Ian N Bruce, Caroline Gordon, Susan Manzi, Janis McCaffrey and Peter E Lipsky
Annals of the rheumatic diseases, v 78(6), pp 729-735
01 Jun 2019
PMID: 30636212
url
https://research.birmingham.ac.uk/portal/en/publications/current-challenges-in-the-development-of-new-treatments-for-lupus(e1b4999f-0c71-414f-ad6b-ac1321da7be1).htmlView
Open

Abstract

Biomarkers - blood Clinical Trials as Topic - methods Drug Development - methods Humans Immunosuppressive Agents - therapeutic use Lupus Erythematosus, Systemic - diagnosis Lupus Erythematosus, Systemic - drug therapy Research Design Severity of Illness Index Treatment Outcome
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a considerable impact on patients' quality of life. Despite the plethora of clinical trials for SLE since the turn of the millennium, only one new treatment has been approved for the condition, and the overall pace of successful drug development remains slow. Nevertheless, the myriad of clinical studies has yielded insights that have informed and refined our understanding of eligibility criteria, outcome measures and trial design in SLE. In this review, we highlight the achievements of clinical trials as well as the major pitfalls that have been identified in drug development for SLE and, in doing so, identify areas where collaboration and consensus will be important to facilitate progress.

Metrics

9 Record Views
41 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Rheumatology
Logo image